<DOC>
	<DOCNO>NCT00609947</DOCNO>
	<brief_summary>The objective study verify safety efficacy Endeavor Zotarolimus-Eluting Coronary Stent System improve coronary luminal diameter patient ischemic heart disease due de novo lesion length ≤27 mm native coronary artery reference vessel ≥ 2.25 mm ≤ 2.75 mm .</brief_summary>
	<brief_title>Endeavor Zotarolimus - Eluting Stent Treatment Lesions Small Native Coronary Arteries .</brief_title>
	<detailed_description />
	<mesh_term>Coronary Artery Disease</mesh_term>
	<mesh_term>Myocardial Ischemia</mesh_term>
	<mesh_term>Coronary Disease</mesh_term>
	<mesh_term>Sirolimus</mesh_term>
	<criteria>GENERAL INCLUSION CRITERIA : The patient ≥18 year age . The patient clinical evidence ischemic heart disease , stable unstable angina , silent ischemia , positive functional study . The patient acceptable candidate Percutaneous Transluminal Coronary Angiography ( PTCA ) , stenting , emergent Coronary Artery Bypass Grafting ( CABG ) surgery . Female patient childbearing potential must negative pregnancy test within 7 day procedure . The patient patient 's legal representative inform nature study agree provision provide write informed consent approve Institutional Review Board respective clinical site . The patient agree return research facility require postprocedure followup visit . ANGIOGRAPHIC INCLUSION CRITERIA 1 . The target lesion/vessel must meet following criterion : 1 . The patient require treatment either : A single de novo lesion locate native coronary artery amenable treatment 2.25mm , 2.5mm 2.75mm stent , Two de novo lesion locate separate target vessel , least one target lesion amenable treatment 2.25mm , 2.5mm , 2.75mm stent second lesion amenable treatment 2.25mm , 2.5mm , 2.75mm stent 3.0mm 3.5mm approve Endeavor stent . 2 . The lesion ( ) must ≤ 27mm length . 3 . The lesion ( ) must stenosis ≥ 50 % &lt; 100 % . 4 . The vessel ( ) ( ) thrombolysis myocardial infarction ( TIMI ) flow 2 great . 5 . The target vessel reference diameter must ≥ 2.25mm ≤ 2.75mm second target vessel reference diameter , present , must ≥ 2.25mm ≤ 3.5mm . 6 . All target lesion treat Medtronic Endeavor stent . GENERAL EXCLUSION CRITERIA : 1 . Known hypersensitivity contraindication aspirin , heparin , bivalirudin , ticlopidine , clopidogrel , cobalt , nickel , chromium , molybdenum , polymer coating , sensitivity contrast medium , adequately premedicated 2 . History allergic reaction significant sensitivity drug zotarolimus , rapamycin , tacrolimus , everolimus , analogue derivative 3 . Platelet count &lt; 100,000 cells/mm³ &gt; 700,000 cells/mm³ , white blood cell count &lt; 3,000 cells/mm³ 4 . Serum creatinine level &gt; 2.0 mg/dl within 7 day prior index procedure 5 . Evidence acute MI within 72 hour intend index procedure 6 . Planned PCI vessel within 30 day pre postindex procedure and/or plan PCI target vessel ( ) within 12 month postprocedure . 7 . During index procedure , target lesion ( ) require treatment device PTCA prior stent placement 8 . History stroke transient ischemic attack ( TIA ) within prior 6 month 9 . Active peptic ulcer upper gastrointestinal ( GI ) bleeding within prior 6 month . 10 . History bleed diathesis coagulopathy patient refuse blood transfusion . 11 . Concurrent medical condition life expectancy le 12 month . 12 . Any previous plan treatment target vessel antirestenotic therapy include limited brachytherapy . 13 . Currently participate investigational drug another device study complete primary endpoint clinically interfere current study endpoint ; require coronary angiography , IVUS coronary artery imaging procedure . 14 . Documented leave ventricular ejection fraction ( LVEF ) &lt; 30 % recent evaluation . 15 . Inability comply protocol require medication regimen ANGIOGRAPHIC EXCLUSION CRITERIA 1 . Target lesion ( ) locate native vessel distal anastomosis saphenous vein graft left/right internal mammary artery bypass &gt; 40 % diameter stenosis anywhere within graft . 2 . Previous stenting target vessel ( ) unless follow condition meet : . It least 9 month since previous stenting , b . The target lesion ( ) is/are least 15mm away previously place stent . 3 . Target vessel lesion &gt; 40 % diameter stenosis base visual estimate online QCA 4 . Target vessel ( ) has/have evidence thrombus 5 . Target vessel ( ) excessively tortuous ( two bend ≥90º reach target lesion ) 6 . Target lesion follow characteristic : 1 . Location aortoostial , unprotected leave main lesion , within 5 mm origin leave anterior descending ( LAD ) , leave circumflex ( LCX ) , right coronary artery ( RCA ) 2 . Involves side branch &gt; 2.0 mm diameter 3 . Is distal &gt; 45º bend vessel 4 . Is severely calcified 5 . Involves bifurcation 7 . Unprotected leave main coronary artery disease</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2015</verification_date>
</DOC>